{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:36:32Z","timestamp":1790282192090,"version":"4.1.0"},"reference-count":65,"publisher":"Akademiai Kiado Zrt.","issue":"12","license":[{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2026,3,22]]},"abstract":"<jats:p>Az albumin a legfontosabb plazmaprotein, t\u00f6bbek k\u00f6z\u00f6tt kulcsszerepet j\u00e1tszik az\n                    oncoticus nyom\u00e1s fenntart\u00e1s\u00e1ban, az inflammatorikus v\u00e1lasz modul\u00e1l\u00e1s\u00e1ban,\n                    valamint endog\u00e9n \u00e9s exog\u00e9n anyagok sz\u00e1ll\u00edt\u00e1s\u00e1ban. Az albumin immunmodul\u00e1l\u00f3 \u00e9s\n                    antioxid\u00e1ns tulajdons\u00e1gai tov\u00e1bb indokolj\u00e1k a sziszt\u00e9m\u00e1s gyullad\u00e1s m\u00e9rs\u00e9kl\u00e9s\u00e9ben\n                    bet\u00f6lt\u00f6tt szerep\u00e9t. Az albuminp\u00f3tl\u00e1s ter\u00e1pi\u00e1s szerepe kritikus \u00e1llapot\u00fa\n                    betegekben az intenz\u00edv oszt\u00e1lyos ell\u00e1t\u00e1s r\u00e9szek\u00e9nt egyre nagyobb figyelmet kap.\n                    Klinikai vizsg\u00e1latok \u00e9s metaanal\u00edzisek azt mutatj\u00e1k, hogy az albumin alkalmaz\u00e1sa\n                    jav\u00edthatja a hemodinamikai stabilit\u00e1st, fokozhatja a folyad\u00e9kbevitelre adott\n                    hemodinamikai v\u00e1laszk\u00e9szs\u00e9get, \u00e9s cs\u00f6kkentheti a pozit\u00edv folyad\u00e9km\u00e9rleget s\u00falyos\n                    szepszisben \u00e9s szeptikus sokkban, k\u00fcl\u00f6n\u00f6sen a hypoalbuminaemi\u00e1s betegekben. A\n                    hypoalbuminaemia szeptikus betegekben gyakori, a kedvez\u0151tlen kimenetel, valamint\n                    a szervi diszfunkci\u00f3 \u00e9s a fokozott \u00e1llapotroml\u00e1s fontos jelz\u0151je. Kritikus\n                    \u00e1llapot\u00fa betegekben a hypoalbuminaemia az intenz\u00edv oszt\u00e1lyos morbidit\u00e1s \u00e9s\n                    mortalit\u00e1s egyik meghat\u00e1roz\u00f3 t\u00e9nyez\u0151je, kialakul\u00e1s\u00e1ban kulcsszerepet j\u00e1tszanak a\n                    gyullad\u00e1s \u00e9s a szepszis sor\u00e1n fell\u00e9p\u0151 szab\u00e1lyozatlan immunv\u00e1laszok, amelyek\n                    endotheldiszfunkci\u00f3hoz \u00e9s fokozott kapill\u00e1ris sziv\u00e1rg\u00e1shoz vezetnek. A\n                    ter\u00e1pi\u00e1ban haszn\u00e1lt jelenlegi ir\u00e1nyelvek egy\u00e9nre szabott folyad\u00e9kter\u00e1pi\u00e1t\n                    javasolnak. Az albumin ad\u00e1s\u00e1t els\u0151sorban azokn\u00e1l a betegekn\u00e9l prefer\u00e1lj\u00e1k, akik\n                    nagy mennyis\u00e9g\u0171 krisztalloid folyad\u00e9kter\u00e1pi\u00e1t ig\u00e9nyelnek, \u00e9s\/vagy alacsony\n                    sz\u00e9rumalbuminszinttel rendelkeznek. Annak ellen\u00e9re, hogy az el\u0151ny\u00f6k ismertek, az\n                    albumin optim\u00e1lis alkalmaz\u00e1si ideje, d\u00f3zisa \u00e9s a megfelel\u0151 betegkiv\u00e1laszt\u00e1s\n                    tov\u00e1bbi jelenlegi kutat\u00e1s t\u00e1rgya. Az albuminszint nemcsak a betegs\u00e9g\n                    s\u00falyoss\u00e1g\u00e1nak egyik jellemz\u0151je, a c\u00e9l\u00e9rt\u00e9khez k\u00f6zeli szintre t\u00f6rt\u00e9n\u0151 be\u00e1ll\u00edt\u00e1sa\n                    racion\u00e1lis ter\u00e1pi\u00e1s opci\u00f3 is egyben az intenz\u00edv oszt\u00e1lyon, amely bizony\u00edt\u00e9kokon\n                    alapul\u00f3 megk\u00f6zel\u00edt\u00e9s mellett esetlegesen jav\u00edthatja a kritikus, szeptikus\n                    betegek \u00e1llapot\u00e1t, kimenetel\u00e9t. Orv Hetil. 2026; 167(12): 456\u2013465.<\/jats:p>","DOI":"10.1556\/650.2026.33507","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:39:59Z","timestamp":1774280399000},"page":"456-465","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":1,"title":["Az albumin szerepe a kritikus \u00e1llapot\u00fa betegek intenz\u00edv ter\u00e1pi\u00e1j\u00e1ban"],"prefix":"10.1556","volume":"167","author":[{"given":"Kamilla","family":"Domokos","sequence":"first","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, Aneszteziol\u00f3giai \u00e9s Intenz\u00edv Ter\u00e1pi\u00e1s Int\u00e9zet P\u00e9cs, Ifj\u00fas\u00e1g u. 13., 7624 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcell","family":"Ulrich","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar P\u00e9cs Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panna","family":"T\u00f3th","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar P\u00e9cs Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4228-6006","authenticated-orcid":true,"given":"Bal\u00e1zs","family":"S\u00fct\u0151","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, Aneszteziol\u00f3giai \u00e9s Intenz\u00edv Ter\u00e1pi\u00e1s Int\u00e9zet P\u00e9cs, Ifj\u00fas\u00e1g u. 13., 7624 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Farrugia A. Albumin usage in clinical medicine: tradition or\n                    therapeutic? Transfus Med Rev. 2010; 24: 56-63.\n                        https:\/\/doi.org\/10.1016\/j.tmrv.2009.09.005","DOI":"10.1016\/j.tmrv.2009.09.005"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Bracht H, Georgieff M, Matejovic M, et al. Human serum albumin as a\n                    resuscitation fluid. Less SAFE than presumed? Crit Care Med. 2011; 39:\n                    1584-1585.\n                    https:\/\/doi.org\/10.1097\/CCM.0b013e318215bb62","DOI":"10.1097\/CCM.0b013e318215bb62"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Finfer S, Liu B, Taylor C, et al. Resuscitation fluid use in\n                    critically ill adults: an international cross-sectional study in 391 intensive\n                    care units. Crit Care 2010; 14: R185.\n                    https:\/\/doi.org\/10.1186\/cc9293","DOI":"10.1186\/cc9293"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Hammond NE, Taylor C, Finfer S, et al. Patterns of intravenous fluid\n                    resuscitation use in adult intensive care patients between 2007 and 2014: an\n                    international cross-sectional study. PLoS ONE 2017; 12: e0176292.\n                        https:\/\/doi.org\/10.1371\/journal.pone.0176292","DOI":"10.1371\/journal.pone.0176292"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Melia D, Post B. Human albumin solutions in intensive care: a\n                    review. J Intensive Care Soc. 2020; 22: 248-254.\n                        https:\/\/doi.org\/10.1177\/1751143720961245","DOI":"10.1177\/1751143720961245"},{"key":"R6","unstructured":"Lantos J, Csontos C, M\u00fchl D, et al. Changes in leukocyte surface\n                    markers during treatment of critically ill patients. Br J Surg. 2010; 97:\n                    76-77."},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Joannidis M, Wiedermann CJ, Ostermann M. Ten myths about albumin.\n                    Int Care Med. 2022; 48: 602-605.\n                        https:\/\/doi.org\/10.1007\/s00134-022-06655-8","DOI":"10.1007\/s00134-022-06655-8"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Hahn O, Szij\u00e1rt\u00f3 A, Pekli D, et al. The complex treatment of\n                    hepatocellular carcinoma. [A hepatocellularis carcinoma komplex kezel\u00e9se.\n                    Konszenzuskonferencia, Budapest, 2021. \u00e1prilis 24.] Orv Hetil. 2021; 162(Suppl\n                    2): 2-31. [Hungarian]\n                    https:\/\/doi.org\/10.1556\/650.2021.32431","DOI":"10.1556\/650.2021.32431"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Wiedermann CJ. Moderator effect of hypoalbuminemia in volume\n                    resuscitation and plasma expansion with intravenous albumin solution. Int J Mol\n                    Sci. 2022; 23: 14175.\n                    https:\/\/doi.org\/10.3390\/ijms232214175","DOI":"10.3390\/ijms232214175"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Franch-Arcas G. The meaning of hypoalbuminaemia in clinical\n                    practice. Clin Nutr. 2001; 20: 265-269.\n                        https:\/\/doi.org\/10.1054\/clnu.2001.0438","DOI":"10.1054\/clnu.2001.0438"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Gatta A, Verardo A, Bolognesi M. Hypoalbuminemia. Intern Emerg Med.\n                    2012; 7(Suppl 3): S193-S199.\n                        https:\/\/doi.org\/10.1007\/s11739-012-0802-0","DOI":"10.1007\/s11739-012-0802-0"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Holub L, Szab\u00f3 BG, Z\u00e1vorszky L, et al. Pharmacokinetic and\n                    pharmacodynamic considerations of antibiotic therapy among critically ill adult\n                    patients with sepsis. [Kritikus \u00e1llapot\u00fa, szeptikus feln\u0151tt betegek\n                    antibiotikumkezel\u00e9s\u00e9nek farmakokinetikai \u00e9s farmakodinamikai megfontol\u00e1sai.] Orv\n                    Hetil. 2024; 165: 403-415. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2024.33001","DOI":"10.1556\/650.2024.33001"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"S\u00fct\u0151 B, Bagoly T, B\u00f6rzsei R, et al. Surgery and sepsis increase\n                    somatostatin-like immunoreactivity in the human plasma. Peptides 2010; 31:\n                    1208-1212.\n                    https:\/\/doi.org\/10.1016\/j.peptides.2010.03.018","DOI":"10.1016\/j.peptides.2010.03.018"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"S\u00fct\u0151 B, Szitter I, Bagoly T, et al. Plasma somatostatin-like\n                    immunoreactivity increases in the plasma of septic patients and rats with\n                    systemic inflammatory reaction: experimental evidence for its sensory origin and\n                    protective role. Peptides 2014; 54: 49-57.\n                        https:\/\/doi.org\/10.1016\/j.peptides.2014.01.006","DOI":"10.1016\/j.peptides.2014.01.006"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"S\u00fct\u0151 B, Kolumb\u00e1n B, Szab\u00f3 \u00c9, et al. Plasma somatostatin levels\n                    increase during scoliosis surgery, but not herniated disc operations: results of\n                    a pilot study. Biomedicines 2023; 11: 2154.\n                        https:\/\/doi.org\/10.3390\/biomedicines11082154","DOI":"10.3390\/biomedicines11082154"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"S\u00fct\u0151 B, Kun J, Bagoly T, et al. Plasma somatostatin levels are lower\n                    in patients with coronary stenosis and significantly increase after stent\n                    implantation. J Clin Med. 2024; 13: 4727.\n                        https:\/\/doi.org\/10.3390\/jcm13164727","DOI":"10.3390\/jcm13164727"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Szab\u00f3n\u00e9 R\u00e9v\u00e9sz E, Montsk\u00f3 V, Altorjay \u00c1, et al. Differences in\n                    bacterial flora detected during negative pressure wound treatment of different\n                    origin of infected wounds in stick and sponge cultures. [A k\u00fcl\u00f6nb\u00f6z\u0151 eredet\u0171\n                    fert\u0151z\u00f6tt sebek negat\u00edv nyom\u00e1s\u00fa sebkezel\u00e9se sor\u00e1n \u00e9szlelt bakteri\u00e1lis fl\u00f3ra\n                    elt\u00e9r\u00e9se p\u00e1lc\u00e1s \u00e9s szivacsmint\u00e1s teny\u00e9szt\u00e9sek sor\u00e1n.] Orv Hetil. 2024; 165:\n                    59-68. [Hungarian]\n                    https:\/\/doi.org\/10.1556\/650.2024.32947","DOI":"10.1556\/650.2024.32947"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Zhang F, Liu X, Tan Z, et al. Effect of postoperative\n                    hypoalbuminemia and supplement of human serum albumin on the development of\n                    surgical site infection following spinal fusion surgery: a retrospective study.\n                    Eur Spine J. 2020; 29: 1483-1489.\n                        https:\/\/doi.org\/10.1007\/s00586-020-06306-w","DOI":"10.1007\/s00586-020-06306-w"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Csom\u00f3s \u00c1, Klicsu L, L\u00e1szl\u00f3 I, et al. Artificial nutrition in\n                    intensive care: Hungarian results of the EuroPN study. [Klinikai t\u00e1pl\u00e1l\u00e1s az\n                    intenz\u00edv oszt\u00e1lyon: az EuroPN-vizsg\u00e1lat magyarorsz\u00e1gi eredm\u00e9nyei.] Orv Hetil.\n                    2024; 165: 531-537. [Hungarian]\n                        https:\/\/doi.org\/10.1556\/650.2024.33017","DOI":"10.1556\/650.2024.33017"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Desgagn\u00e9s N, King JA, Kline GA, et al. Use of albumin-adjusted\n                    calcium measurements in clinical practice. JAMA Netw Open 2025; 8: e2455251.\n                    Erratum: JAMA Netw Open 2025; 8: e256345.\n                        https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.55251","DOI":"10.1001\/jamanetworkopen.2024.55251"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Kwok CS, Krupa L, Mahtani A, et al. Albumin reduces\n                    paracentesis-induced circulatory dysfunction and reduces death and renal\n                    impairment among patients with cirrhosis and infection: a systematic review and\n                    meta-analysis. Biomed Res Int. 2013; 2013: 295153.\n                        https:\/\/doi.org\/10.1155\/2013\/295153","DOI":"10.1155\/2013\/295153"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Gin\u00e8s P, Tit\u00f3 L, Arroyo V, et al. Randomized comparative study of\n                    therapeutic paracentesis with and without intravenous albumin in cirrhosis.\n                    Gastroenterology 1988; 94: 1493-1502.\n                        https:\/\/doi.org\/10.1016\/0016-5085(88)90691-9","DOI":"10.1016\/0016-5085(88)90691-9"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Xu X, Ding H, Jia J, et al. Chinese guidelines on the management of\n                    ascites in cirrhosis: Chinese Society of Hepatology, Chinese Medical\n                    Association. Hepatol Int. 2024; 18: 1071-1089.\n                        https:\/\/doi.org\/10.1007\/s12072-024-10697-z","DOI":"10.1007\/s12072-024-10697-z"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Aithal GP, Palaniyappan N, China L, et al. Guidelines on the\n                    management of ascites in cirrhosis. Gut 2021; 70: 9-29.\n                        https:\/\/doi.org\/10.1136\/gutjnl-2020-321790","DOI":"10.1136\/gutjnl-2020-321790"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs E, Maimeri N, Orlando F, et al. Factors improving mortality\n                    in critically ill patients with liver failure: a systematic review. Physiol Int.\n                    2023; 110: 211-226.\n                    https:\/\/doi.org\/10.1556\/2060.2023.00211","DOI":"10.1556\/2060.2023.00211"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on\n                    renal impairment and mortality in patients with cirrhosis and spontaneous\n                    bacterial peritonitis. N Engl J Med. 1999; 341: 403-409.\n                        https:\/\/doi.org\/10.1056\/NEJM199908053410603","DOI":"10.1056\/NEJM199908053410603"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"EASL clinical practice guidelines for the management of patients\n                    with decompensated cirrhosis. J Hepatol. 2018; 69: 406-460. Corrigendum to \u201cEASL\n                    Clinical Practice Guidelines for the management of patients with decompensated\n                    cirrhosis.\u201d Erratum: J Hepatol. 2018; 69: 1207.\n                        https:\/\/doi.org\/10.1016\/j.jhep.2018.08.009","DOI":"10.1016\/j.jhep.2018.08.009"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Lee EH, Kim WJ, Kim JY, et al. Effect of exogenous albumin on the\n                    incidence of postoperative acute kidney injury in patients undergoing off-pump\n                    coronary artery bypass surgery with a preoperative albumin level of less than\n                    4.0 g\/dl. Anesthesiology 2016; 124: 1001-1011.\n                        https:\/\/doi.org\/10.1097\/ALN.0000000000001051","DOI":"10.1097\/ALN.0000000000001051"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign:\n                    international guidelines for management of sepsis and septic shock: 2016.\n                    Intensive Care Med. 2017; 43: 304-377.\n                        https:\/\/doi.org\/10.1007\/s00134-017-4683-6","DOI":"10.1007\/s00134-017-4683-6"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Dellinger RP, Rhodes A, Evans L, et al. Surviving Sepsis Campaign.\n                    Crit Care Med. 2023; 51: 431-444.\n                        https:\/\/doi.org\/10.1097\/CCM.0000000000005804","DOI":"10.1097\/CCM.0000000000005804"},{"key":"R31","unstructured":"Skillman JJ, Restall DS, Salzman EW. Randomized trial of albumin vs.\n                    electrolyte solutions during abdominal aortic operations. Surgery 1975; 78:\n                    291-303."},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Reviewers, Cochrane Injuries Group Albumin. Human albumin\n                    administration in critically ill patients: systematic review of randomised\n                    controlled trials. BMJ 1998; 317: 235-240.\n                        https:\/\/doi.org\/10.1136\/bmj.317.7153.235","DOI":"10.1136\/bmj.317.7153.235"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Stockwell MA, Scott A, Day A, et al. Colloid solutions in the\n                    critically ill: a randomised comparison of albumin and polygeline 2. Serum\n                    albumin concentration and incidences of pulmonary oedema and acute renal\n                    failure. Anaesthesia 1992; 47: 7-9.\n                        https:\/\/doi.org\/10.1111\/j.1365-2044.1992.tb01942.x","DOI":"10.1111\/j.1365-2044.1992.tb01942.x"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Finfer S, Bellom R, Boyce N, et al. A comparison of albumin and\n                    saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;\n                    350: 2247-2256. https:\/\/doi.org\/10.1056\/NEJMoa040232","DOI":"10.1056\/NEJMoa040232"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Cooper DJ, Myburgh J, Heritier S, et al. Albumin resuscitation for\n                    traumatic brain injury. Is intracranial hypertension the cause of increased\n                    mortality? J Neurotrauma 2013; 30: 512-518.\n                        https:\/\/doi.org\/10.1089\/neu.2012.2573","DOI":"10.1089\/neu.2012.2573"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Arabi YM, Belley-Cote E, Carsetti A, et al. European Society of\n                    Intensive Care Medicine clinical practice guideline on fluid therapy in adult\n                    critically ill patients. Part 1: the choice of resuscitation fluids. Intensive\n                    Care Med. 2024; 50: 813-831.\n                        https:\/\/doi.org\/10.1007\/s00134-024-07369-9","DOI":"10.1007\/s00134-024-07369-9"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Jacob M, Chappell D, Conzen P, et al. Small-volume resuscitation\n                    with hyperoncotic albumin: a systematic review of randomized clinical trials.\n                    Crit Care 2008; 12: R34.\n                    https:\/\/doi.org\/10.1186\/cc6812","DOI":"10.1186\/cc6812"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Myburgh JA. The evidence for small-volume resuscitation with\n                    hyperoncotic albumin in critical illness. Crit Care 2008; 12: 143.\n                        https:\/\/doi.org\/10.1186\/cc6882","DOI":"10.1186\/cc6882"},{"key":"R39","doi-asserted-by":"crossref","unstructured":"M\u00e5rtensson J, Bihari S, Bannard-Smith J, et al. Small volume\n                    resuscitation with 20% albumin in intensive care: physiological effects. The\n                    SWIPE randomised clinical trial. Intensive Care Med. 2018; 44: 1797-1806.\n                        https:\/\/doi.org\/10.1007\/s00134-018-5253-2","DOI":"10.1007\/s00134-018-5253-2"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"S\u00fct\u0151 B, Domokos K. Perioperative aspects of anaphylaxis. [Az\n                    anafilaxia perioperat\u00edv vonatkoz\u00e1sai.] Orv Hetil. 2023; 164: 871-877.\n                    [Hungarian] https:\/\/doi.org\/10.1556\/650.2023.32789","DOI":"10.1556\/650.2023.32789"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Abdel-Aziz S, Abdelnaem E, Kumar N, et al. Anaphylactoid shock with\n                    infusion of 5% albumin in a patient under general anesthesia. Open J\n                    Anesthesiol. 2012; 2: 214-216.\n                        https:\/\/doi.org\/10.4236\/ojanes.2012.25048","DOI":"10.4236\/ojanes.2012.25048"},{"key":"R42","doi-asserted-by":"crossref","unstructured":"Carvey MM, Glauser J. When to reach for albumin in sepsis and septic\n                    shock: a step-by-step reference guide for emergency physicians. Curr Emerg Hosp\n                    Med Rep. 2025; 13: 23.\n                    https:\/\/doi.org\/10.1007\/s40138-025-00327-9","DOI":"10.1007\/s40138-025-00327-9"},{"key":"R43","doi-asserted-by":"crossref","unstructured":"Finfer S, McEvoy S, Bellomo R, et al. Impact of albumin compared to\n                    saline on organ function and mortality of patients with severe sepsis. Intensive\n                    Care Med. 2011; 37: 86-96.\n                    https:\/\/doi.org\/10.1007\/s00134-010-2039-6","DOI":"10.1007\/s00134-010-2039-6"},{"key":"R44","unstructured":"Charpentier J, Mira JP. Efficacy and tolerance of hyperoncotic\n                    albumin administration in septic shock patients: The EARSS study. Intensive Care\n                    Med. 2011; 37: S115."},{"key":"R45","doi-asserted-by":"crossref","unstructured":"Caironi P, Tognoni G, Masson S, et al. Albumin replacement in\n                    patients with severe sepsis or septic shock. N Engl J Med. 2014; 370: 1412-1421.\n                        https:\/\/doi.org\/10.1056\/NEJMoa1305727","DOI":"10.1056\/NEJMoa1305727"},{"key":"R46","doi-asserted-by":"crossref","unstructured":"Wiedermann CJ, Joannidis M. Albumin replacement in severe sepsis or\n                    septic shock. N Engl J Med. 2014; 371: 83-84.\n                        https:\/\/doi.org\/10.1056\/NEJMc1405675","DOI":"10.1056\/NEJMc1405675"},{"key":"R47","doi-asserted-by":"crossref","unstructured":"Lee Park CH, de Almeida JP, de Oliveira GQ, et al. Lactated Ringer\u2019s\n                    versus 4% albumin on lactated Ringer\u2019s in early sepsis therapy in cancer\n                    patients: a pilot single-center randomized trial. Crit Care Med. 2019; 47:\n                    e798-e805.\n                    https:\/\/doi.org\/10.1097\/CCM.0000000000003900","DOI":"10.1097\/CCM.0000000000003900"},{"key":"R48","doi-asserted-by":"crossref","unstructured":"Gray AJ, Oatey K, Grahamslaw J, et al. Albumin versus balanced\n                    crystalloid for the early resuscitation of sepsis: an open parallel-group\n                    randomized feasibility trial. The ABC-Sepsis Trial. Crit Care Med. 2024; 52:\n                    1520-1532.\n                    https:\/\/doi.org\/10.1097\/CCM.0000000000006348","DOI":"10.1097\/CCM.0000000000006348"},{"key":"R49","doi-asserted-by":"crossref","unstructured":"Philips CA, Maiwall R, Sharma MK, et al. Comparison of 5% human\n                    albumin and normal saline for fluid resuscitation in sepsis induced hypotension\n                    among patients with cirrhosis (FRISC study): a randomized controlled trial.\n                    Hepatol Int. 2021; 15: 983-994.\n                        https:\/\/doi.org\/10.1007\/s12072-021-10164-z","DOI":"10.1007\/s12072-021-10164-z"},{"key":"R50","doi-asserted-by":"crossref","unstructured":"Gobin N, Coltamai L, Burnier M, et al. Resistance to loop diuretics\n                    in clinical practice. [R\u00e9sistance aux diur\u00e9tiques de l\u2019anse en clinique.] Rev\n                    Med Suisse 2010; 6: 438-442. [French]\n                        https:\/\/doi.org\/10.53738\/REVMED.2010.6.238.0438","DOI":"10.53738\/REVMED.2010.6.238.0438"},{"key":"R51","doi-asserted-by":"crossref","unstructured":"Oh SW, Han SY. Loop diuretics in clinical practice. Electrolyte\n                    Blood Press 2015; 13: 17-21.\n                    https:\/\/doi.org\/10.5049\/EBP.2015.13.1.17","DOI":"10.5049\/EBP.2015.13.1.17"},{"key":"R52","doi-asserted-by":"crossref","unstructured":"Martin GS, Moss M, Wheeler AP, et al. A randomized, controlled trial\n                    of furosemide with or without albumin in hypoproteinemic patients with acute\n                    lung injury. Crit Care Med. 2005; 33: 1681-1687.\n                        https:\/\/doi.org\/10.1097\/01.CCM.0000171539.47006.02","DOI":"10.1097\/01.CCM.0000171539.47006.02"},{"key":"R53","doi-asserted-by":"crossref","unstructured":"Lee TH, Kuo G, Chang CH, et al. Diuretic effect of co-administration\n                    of furosemide and albumin in comparison to furosemide therapy alone: an updated\n                    systematic review and meta-analysis. PLOS ONE 2021; 16: e0260312.\n                        https:\/\/doi.org\/10.1371\/journal.pone.0260312","DOI":"10.1371\/journal.pone.0260312"},{"key":"R54","doi-asserted-by":"crossref","unstructured":"Oczkowski SJ, Klotz L, Mazzetti I, et al. Furosemide and albumin for\n                    diuresis of edema (FADE): A parallel-group, blinded, pilot randomized controlled\n                    trial. J Crit Care 2018; 48: 462-467.\n                        https:\/\/doi.org\/10.1016\/j.jcrc.2018.07.020","DOI":"10.1016\/j.jcrc.2018.07.020"},{"key":"R55","doi-asserted-by":"crossref","unstructured":"Kitsios GD, Mascari P, Ettunsi R, et al. Co-administration of\n                    furosemide with albumin for overcoming diuretic resistance in patients with\n                    hypoalbuminemia: a meta-analysis. J Crit Care 2014; 29: 253-259.\n                        https:\/\/doi.org\/10.1016\/j.jcrc.2013.10.004","DOI":"10.1016\/j.jcrc.2013.10.004"},{"key":"R56","doi-asserted-by":"crossref","unstructured":"Ernest D, Belzberg AS, Dodek PM. Distribution of normal saline and\n                    5% albumin infusions in septic patients. Crit Care Med. 1999; 27: 46-50.\n                        https:\/\/doi.org\/10.1097\/00003246-199901000-00025","DOI":"10.1097\/00003246-199901000-00025"},{"key":"R57","doi-asserted-by":"crossref","unstructured":"Martin GS, Mangialardi RJ, Wheeler AP, et al. Albumin and furosemide\n                    therapy in hypoproteinemic patients with acute lung injury. Crit Care Med. 2002;\n                    30: 2175-2182.\n                    https:\/\/doi.org\/10.1097\/00003246-200210000-00001","DOI":"10.1097\/00003246-200210000-00001"},{"key":"R58","doi-asserted-by":"crossref","unstructured":"Salerno F, Gerbes A, Gin\u00e8s P, et al. Diagnosis, prevention and\n                    treatment of hepatorenal syndrome in cirrhosis. Postgrad Med J. 2008; 84:\n                    662-670. https:\/\/doi.org\/10.1136\/gut.2006.107789","DOI":"10.1136\/gut.2006.107789"},{"key":"R59","doi-asserted-by":"crossref","unstructured":"Bai Z, Lai Y, Han K, et al. Human albumin for adults with sepsis: an\n                    updated systematic review and meta-analysis of randomized controlled trials.\n                    Medicine (Baltimore) 2024; 103: e40983.\n                        https:\/\/doi.org\/10.1097\/MD.0000000000040983","DOI":"10.1097\/MD.0000000000040983"},{"key":"R60","doi-asserted-by":"crossref","unstructured":"Gabarre P, Desnos C, Morin A, et al. Albumin versus saline infusion\n                    for sepsis-related peripheral tissue hypoperfusion: a proof-of-concept\n                    prospective study. Crit Care 2024; 28: 43.\n                        https:\/\/doi.org\/10.1186\/s13054-024-04827-0","DOI":"10.1186\/s13054-024-04827-0"},{"key":"R61","doi-asserted-by":"crossref","unstructured":"Geng L, Tian X, Gao Z, et al. Different concentrations of albumin\n                    versus crystalloid in patients with sepsis and septic shock: a meta-analysis of\n                    randomized clinical trials. J Int Care Med. 2023; 38: 679-689.\n                        https:\/\/doi.org\/10.1177\/08850666231170778","DOI":"10.1177\/08850666231170778"},{"key":"R62","doi-asserted-by":"crossref","unstructured":"Wiedermann CJ. Use of hyperoncotic human albumin solution in severe\n                    traumatic brain injury revisited - a narrative review and meta-analysis. J Clin\n                    Med. 2022; 11: 2662.\n                    https:\/\/doi.org\/10.3390\/jcm11092662","DOI":"10.3390\/jcm11092662"},{"key":"R63","doi-asserted-by":"crossref","unstructured":"Wiedermann CJ. Phases of fluid management and the roles of human\n                    albumin solution in perioperative and critically ill patients. Curr Med Res Opin\n                    2020; 36: 1961-1973.\n                    https:\/\/doi.org\/10.1080\/03007995.2020.1840970","DOI":"10.1080\/03007995.2020.1840970"},{"key":"R64","doi-asserted-by":"crossref","unstructured":"Abedi F, Zarei B, Elyasi S. Albumin: a comprehensive review and\n                    practical guideline for clinical use. Eur J Clin Pharmacol. 2024; 80: 1151-1169.\n                        https:\/\/doi.org\/10.1007\/s00228-024-03664-y","DOI":"10.1007\/s00228-024-03664-y"},{"key":"R65","doi-asserted-by":"crossref","unstructured":"Spada A, Emami J, Tuszynski JA, et al. The uniqueness of albumin as\n                    a carrier in nanodrug delivery. Mol Pharm. 2021; 18: 1862-1894.\n                        https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00046","DOI":"10.1021\/acs.molpharmaceut.1c00046"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/167\/12\/article-p456.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/167\/12\/article-p456.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/167\/12\/article-p456.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:40:13Z","timestamp":1774280413000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/167\/12\/article-p456.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,22]]},"references-count":65,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.1556\/650.2026.33507","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,22]]}}}